Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1250MR)

This product GTTS-WQ1250MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1250MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1829MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ14985MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ7675MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ3904MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ23MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ14611MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ12231MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ12282MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW